DW 1029M / Dong Wha - LARVOL DELTA

Phase I and Pharmacokinetic Drug-Drug Interaction Study of Metformin, Losartan, and Linagliptin Coadministered with DW1029M in Healthy Volunteers. (PubMed) - Clin Pharmacol Drug Dev - "In addition, coadministration of DW1029M did not have any clinically meaningful effect on the maximum plasma concentration (Cmax,ss ) (Cmax,ss GMR: 87.3, 90% CI: 76.2-100.0 for metformin; Cmax,ss GMR: 90.5, 90% CI: 78.3-104.6 for losartan; and Cmax,ss GMR: 81.4, 90% CI: 69.5-95.3 for linagliptin). Coadministration of DW1029M with metformin, losartan, or linagliptin was well tolerated."

Journal • Biosimilar • Chronic Kidney Disease • Diabetes • Renal Disease

DW1029M, a novel botanical drug candidate, inhibits advanced glycation end product formation, rat lens aldose reductase activity, and TGFβ1 signaling (Am J Physiol Renal Physiol) - "DW1029M inhibits AGE formation via Fe2+ ion chelation. The extract contains 13 active constituents that inhibit AGE formation, eight that inhibit RLAR activity, and one inhibitor of TGFβ1 signaling. Our results suggest DW1029M protects against diabetic nephropathy via blockade of AGE formation, RLAR activity, and TGFβ1 signaling."

Review • Diabetic Nephropathy • Renal Disease